Epidemiological projections of viral-induced hepatocellular carcinoma in the perspective of WHO global hepatitis elimination.
World Health Organization
epidemiology
hepatitis B
hepatitis C
hepatocellular carcinoma
surveillance
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
revised:
19
01
2021
received:
11
11
2020
accepted:
13
02
2021
pubmed:
1
3
2021
medline:
25
6
2021
entrez:
28
2
2021
Statut:
ppublish
Résumé
Hepatitis B is an eminent risk factor for hepatocellular carcinoma (HCC) in Southeast Asia and sub-Saharan Africa, whereas hepatitis C is a key risk factor for HCC in Western Europe and North America. Increased awareness of the global burden of viral hepatitis resulted, in May 2016, in the adoption of the first global health sector strategy on viral hepatitis by the World Health Assembly, which calls for the elimination of viral hepatitis as a public health threat by 2030. Although the incidence of liver cancer resulting from viral infections has increased since the 1990s, the implementation of public health interventions, such as hepatitis B vaccination and antiviral therapies might have reduced the global burdens of HCC. Hepatitis B immunization in infancy has been associated with a reduction in the risk of infant fulminant hepatitis, chronic liver disease, and HCC in Taiwan. Achieving viral hepatitis elimination by 2030 can be accelerated by improving the access to HCC screening programs. HCC surveillance programs in developed countries must be refined to increase an access to personalized surveillance program, whereas the limited access to surveillance and treatment of HCC in developing countries remains a significant public health issue.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
915-927Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(9):1485-1491.
Cancer Epidemiology and Prevention. Fourth Edition, New to This Edition. Oxford, NY: Oxford University Press; 2017:1328.
de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020;8(2):e180-e190.
Akinyemiju T, Abera S, Ahmed M, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level. JAMA Oncol. 2017;3(12):1683-1691.
WHO. Global Hepatitis Report, 2017 [Internet]. World Health Organization. [cited 2020 Apr 6]. http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/
Ni YH, Chang MH, Huang LM, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med. 2001;135(9):796-800.
Chiang C-J, Yang Y-W, You S-L, Lai M-S, Chen C-J. Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. JAMA. 2013;310(9):974-976.
Liang X, Bi S, Yang W, et al. Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. Vaccine. 2009;27(47):6550-6557.
Wiesen E, Diorditsa S, Li X. Progress towards hepatitis B prevention through vaccination in the Western Pacific, 1990-2014. Vaccine. 2016;34(25):2855-2862.
Nayagam S, Thursz M, Sicuri E, et al. Requirements for global elimination of hepatitis B: a modelling study. Lancet Infect Dis. 2016;16(12):1399-1408.
Historical epidemiology of hepatitis C virus (HCV) in selected countries [cited 2020 May 2]. https://www.ncbi.nlm.nih.gov/pubmed/24713004
Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology. 2000;31(3):777-782.
Pépin J, Abou Chakra CN, Pépin E, Nault V, Valiquette L. Evolution of the global burden of viral infections from unsafe medical injections, 2000-2010. PLoS One. 2014;9(6):e99677.
Committee on a National Strategy for the Elimination of Hepatitis B and C, Board on Population Health and Public Health Practice, Health and Medicine Division, National Academies of Sciences, Engineering, and Medicine. Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report [Internet]. Buckley GJ, Strom BL, eds. Washington, DC: National Academies Press (US); 2016 [cited 2020 Apr 6]. http://www.ncbi.nlm.nih.gov/books/NBK368070/
Trickey A, Fraser H, Lim AG, et al. The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. Lancet Gastroenterol Hepatol. 2019;4(6):435-444.
Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161-176.
Shi J, Zhu L, Liu S, Xie W-F. A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Br J Cancer. 2005;92(3):607-612.
Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48(2):335-352.
Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatol Baltim Md. 1995;22(2):432-438.
Singal AG, El-Serag HB. Hepatocellular carcinoma from epidemiology to prevention: translating knowledge into practice. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2015;13(12):2140-2151.
European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182-236.
Lok AS, Seeff LB, Morgan TR, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009;136(1):138-148.
Ioannou GN, Splan MF, Weiss NS, McDonald GB, Beretta L, Lee SP. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2007;5(8):938-945, 945.e1-4.
de Martel C, Maucort-Boulch D, Plummer M, Franceschi S. World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatol Baltim Md. 2015;62(4):1190-1200.
Shimakawa Y, Lemoine M, Njai HF, et al. Natural history of chronic HBV infection in West Africa: a longitudinal population-based study from The Gambia. Gut. 2016;65(12):2007-2016.
Kirk GD, Bah E, Montesano R. Molecular epidemiology of human liver cancer: insights into etiology, pathogenesis and prevention from The Gambia, West Africa. Carcinogenesis. 2006;27(10):2070-2082.
Yang JD, Mohamed EA, Aziz AOA, et al. Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. Lancet Gastroenterol Hepatol. 2017;2(2):103-111.
Liu Z, Jiang Y, Yuan H, et al. The trends in incidence of primary liver cancer caused by specific etiologies: results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention. J Hepatol. 2019;70(4):674-683.
Altekruse SF, Henley SJ, Cucinelli JE, McGlynn KA. Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol. 2014;109(4):542-553.
Tanaka H, Imai Y, Hiramatsu N, et al. Declining incidence of hepatocellular carcinoma in Osaka, Japan, from 1990 to 2003. Ann Intern Med. 2008;148(11):820-826.
Qiu D, Katanoda K, Marugame T, Sobue T. A Joinpoint regression analysis of long-term trends in cancer mortality in Japan (1958-2004). Int J Cancer. 2009;124(2):443-448.
El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264-1273.e1.
Shimakawa Y, Lemoine M. Early age at diagnosis of hepatocellular carcinoma in sub-Saharan Africa. Lancet Gastroenterol Hepatol. 2017;2(6):393.
Chang M-H, You S-L, Chen C-J, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccines: a 20-year follow-up study. J Natl Cancer Inst. 2009;101(19):1348-1355.
Park J-W, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int Off J Int Assoc Study Liver. 2015;35(9):2155-2166.
World Health Organization. Hepatitis B vaccines. Releve Epidemiol Hebd. 2009;84(40):405-419.
World Health Organization. World Hepatitis Day: fast-tracking the elimination of hepatitis B among mothers and children [cited 2020 Nov 3]. https://www.who.int/news/item/27-07-2020-world-hepatitis-day-fast-tracking-the-elimination-of-hepatitis-b-among-mothers-and-children
Shimakawa Y, Yan H-J, Tsuchiya N, et al. Association of early age at establishment of chronic hepatitis B infection with persistent viral replication, liver cirrhosis and hepatocellular carcinoma: A systematic review.PLoS ONE. 2013;8(7): e69430. https://doi.org/10.1371/journal.pone.0069430
Shimakawa Y, Lemoine M, Bottomley C, et al. Birth order and risk of hepatocellular carcinoma in chronic carriers of hepatitis B virus: a case-control study in The Gambia. Liver Int Off J Int Assoc Study Liver. 2015;35(10):2318-2326.
Chang M-H. Natural history and clinical management of chronic hepatitis B virus infection in children. Hepatol Int. 2008;2(Suppl 1):28-36.
Prevention of mother-to-child transmission of hepatitis B virus: guidelines on antiviral prophylaxis in pregnancy [Internet] [cited 2020 Sep 18]. https://www.who.int/publications-detail-redirect/978-92-4-000270-8
Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature. 1991;350(6317):427-428.
Liu Y, Chang C-CH, Marsh GM, Wu F. Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis. Eur J Cancer Oxf Engl 1990. 2012;48(14):2125-2136.
World Health Organization. Mycotoxins [Internet] [cited 2020 May 25]. https://www.who.int/news-room/fact-sheets/detail/mycotoxins
Chen J-G, Egner PA, Ng D, et al. Reduced aflatoxin exposure presages decline in liver cancer mortality in an endemic region of China. Cancer Prev Res Phila Pa. 2013;6(10):1038-1045.
EASL 2017 Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection [Internet] [cited 2020 Apr 13]. https://www.ncbi.nlm.nih.gov/pubmed/28427875
Ahn J, Lim JK, Lee HM, et al. Lower observed hepatocellular carcinoma incidence in chronic hepatitis B patients treated with entecavir: results of the ENUMERATE study. Am J Gastroenterol. 2016;111(9):1297-1304.
Kim WR, Loomba R, Berg T, et al. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. Cancer. 2015;121(20):3631-3638.
Tseng CH, Hsu YC, Chen TH, et al. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020 [Internet] [cited 2020 Oct 24]. https://www.thelancet.com/journals/langas/article/PIIS2468-1253(20)30249-1/fulltext
Ioannou GN, Feld JJ. What are the benefits of a sustained virologic response to direct-acting antiviral therapy for hepatitis C virus infection? Gastroenterology. 2019;156(2):446-460.e2.
Lazarus JV, Wiktor S, Colombo M, Thursz M, EASL International Liver Foundation. Micro-elimination - a path to global elimination of hepatitis C. J Hepatol. 2017;67(4):665-666.
Park H, Wang W, Henry L, Nelson DR. Impact of all-oral direct-acting antivirals on clinical and economic outcomes in patients with chronic hepatitis C in the United States. Hepatol Baltim Md. 2019;69(3):1032-1045.
Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology. 2017;153(4):996-1005.e1.
Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013;158(5 Pt 1):329-337.
Carrat F, Fontaine H, Dorival C, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet. 2019;393(10179):1453-1464.
Papatheodoridis GV, Chan HL-Y, Hansen BE, Janssen HLA, Lampertico P. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol. 2015;62(4):956-967.
Costentin CE, Layese R, Bourcier V, et al. Compliance with hepatocellular carcinoma surveillance guidelines associated with increased lead-time adjusted survival of patients with compensated viral cirrhosis: a multi-center cohort study. Gastroenterology. 2018;155(2):431-442.e10.
Barbara L, Benzi G, Gaiani S, et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology. 1992;16(1):132-137.
Trinchet J-C, Chaffaut C, Bourcier V, et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatol Baltim Md. 2011;54(6):1987-1997.
Papatheodoridis GV, Idilman R, Dalekos GN, et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatol Baltim Md. 2017;66(5):1444-1453.
Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatol Baltim Md. 2018;67(1):358-380.
Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2019;30(5):871-873.
AASLD-IDSA HCV Guidance Panel. Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis Off Publ Infect Dis Soc Am. 2018;67(10):1477-1492.
Kanwal F, Kramer JR, Asch SM, Cao Y, Li L, El-Serag HB. Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents. Hepatol Baltim Md. 2020;71(1):44-55.
Nahon P, Ganne-Carrié N. Management of patients with pre-therapeutic advanced liver fibrosis following HCV eradication. JHEP Rep. 2019;1(6):480-489.
WHO. Global report on access to hepatitis C treatment - Focus on overcoming barriers [Internet] [cited 2020 Dec 27]. https://www.who.int/hepatitis/publications/hep-c-access-report/en/
Heffernan A, Cooke GS, Nayagam S, Thursz M, Hallett TB. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. Lancet Lond Engl. 2019;393(10178):1319-1329.
Waked I, Doss W, El-Sayed MH, et al. The current and future disease burden of chronic hepatitis C virus infection in Egypt. Arab J Gastroenterol Off Publ Pan-Arab Assoc Gastroenterol. 2014;15(2):45-52.
Polaris Observatory. Year of Achieving Elimination Targets (Extrapolated from 2019 Data) [Internet] [cited 2020 Oct 24]. https://cdafound.org/dashboard/polaris/dashboard.html
Razavi H, Robbins S, Zeuzem S, et al. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(5):325-336.
Razavi H, Sanchez Gonzalez Y, Yuen C, Cornberg M. Global timing of hepatitis C virus elimination in high-income countries. Liver Int Off J Int Assoc Study Liver. 2020;40(3):522-529.
Valery PC, Laversanne M, Clark PJ, Petrick JL, McGlynn KA, Bray F. Projections of primary liver cancer to 2030 in 30 countries worldwide. Hepatology. 2018;67(2):600-611.
World Health Organization. Global health sector strategy on viral hepatitis 2016-2021 : towards ending viral hepatitis. WHO-HIV-2016.06-eng.pdf [Internet] [cited 2020 Apr 29]. https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf?sequence=1
Zheng R, Qu C, Zhang S, et al. Liver cancer incidence and mortality in China: temporal trends and projections to 2030. Chin J Cancer Res. 2018;30(6):571-579.
Sun Z, Chen T, Thorgeirsson SS, et al. Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China. Carcinogenesis. 2013;34(8):1800-1805.
Liu Z, Yang Q, Shi O, Ye W, Chen X, Zhang T. The epidemiology of hepatitis B and hepatitis C infections in China from 2004 to 2014: an observational population-based study. J Viral Hepat. 2018;25(12):1543-1554.
Seyda Seydel G, Kucukoglu O, Altinbasv A, et al. Economic growth leads to increase of obesity and associated hepatocellular carcinoma in developing countries. Ann Hepatol. 2016;15(5):662-672.
Wang L, Gao P, Zhang M, et al. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. JAMA. 2017;317(24):2515-2523.
Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol. 2009;50(1):204-210.
Wang F-S, Fan J-G, Zhang Z, Gao B, Wang H-Y. The global burden of liver disease: the major impact of China. Hepatol Baltim Md. 2014;60(6):2099-2108.
Matsumoto K, Wu Y, Kitazawa T, Fujita S, Seto K, Hasegawa T. Cost of illness of hepatocellular carcinoma in Japan: a time trend and future projections. PLoS One. 2018;13(6):e0199188.
Bertuccio P, Turati F, Carioli G, et al. Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol. 2017;67(2):302-309.
Amin J, Law MG, Bartlett M, Kaldor JM, Dore GJ. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet. 2006;368(9539):938-945.
Mittal S, El-Serag HB. Epidemiology of HCC: consider the population. J Clin Gastroenterol. 2013;47:S2-S6.
Ahmed O, Liu L, Gayed A, et al. The changing face of hepatocellular carcinoma: forecasting prevalence of nonalcoholic steatohepatitis and hepatitis C cirrhosis. J Clin Exp Hepatol. 2019;9(1):50-55.
McHutchison JG. Understanding hepatitis C. Am J Manag Care. 2004;10(2 Suppl):S21-S29.
Guadagnino V, Stroffolini T, Rapicetta M, et al. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy. Hepatol Baltim Md. 1997;26(4):1006-1011.
Abdel-Aziz F, Habib M, Mohamed MK, et al. Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. Hepatol Baltim Md. 2000;32(1):111-115.
Yatsuhashi H. Past, present, and future of viral hepatitis C in Japan. Euroasian J Hepato-Gastroenterol. 2016;6(1):49-51.
Saab S, Rheem J, Sundaram V. Hepatitis C infection in the elderly. Dig Dis Sci. 2015;60(11):3170-3180.
World Health Organization. Strategic Advisory Group of Experts on Immunization [Internet] [cited 2021 Jan 17]. https://www.who.int/groups/strategic-advisory-group-of-experts-on-immunization/
Tseng Y-R, Wu J-F, Ni Y-H, et al. Long-term effect of maternal HBeAg on delayed HBeAg seroconversion in offspring with chronic hepatitis B infection. Liver Int Off J Int Assoc Study Liver. 2011;31(9):1373-1380.
Shimakawa Y, Bottomley C, Njie R, Mendy M. The association between maternal hepatitis B e antigen status, as a proxy for perinatal transmission, and the risk of hepatitis B e antigenaemia in Gambian children. BMC Public Health. 2014;30(14):532.
Marion SA, Tomm Pastore M, Pi DW, Mathias RG. Long-term follow-up of hepatitis B vaccine in infants of carrier mothers. Am J Epidemiol. 1994;140(8):734-746.
World Health Organization. Immunization coverage [Internet] [cited 2020 Oct 28]. https://www.who.int/news-room/fact-sheets/detail/immunization-coverage
Bassoum O, Kimura M, Tal Dia A, Lemoine M, Shimakawa Y. Coverage and timeliness of birth dose vaccination in sub-Saharan Africa: a systematic review and meta-analysis. Vaccines. 2020;8(2):301
Machaira M, Papaevangelou V, Vouloumanou EK, Tansarli GS, Falagas ME. Hepatitis B vaccine alone or with hepatitis B immunoglobulin in neonates of HBsAg+/HBeAg− mothers: a systematic review and meta-analysis. J Antimicrob Chemother. 2015;70(2):396-404.
Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ. 2006;332(7537):328-336.
Keane E, Funk AL, Shimakawa Y. Systematic review with meta-analysis: the risk of mother-to-child transmission of hepatitis B virus infection in sub-Saharan Africa. Aliment Pharmacol Ther. 2016;44(10):1005-1017.
Boucheron P, Lu Y, Yoshida K, et al. Accuracy of HBeAg to identify pregnant women at risk of transmitting hepatitis B virus to their neonates: a systematic review and meta-analysis. Lancet Infect Dis. 2021;21(1):85-96.
Funk AL, Lu Y, Yoshida K, et al. Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis. Lancet Infect Dis. 2021;21(1):70-84.
Mohsen A, Bernier A, LeFouler L, et al. Hepatitis C virus acquisition among Egyptians: analysis of a 10-year surveillance of acute hepatitis C. Trop Med Int Health TM IH. 2015;20(1):89-97.
Khan AJ, Luby SP, Fikree F, et al. Unsafe injections and the transmission of hepatitis B and C in a periurban community in Pakistan. Bull World Health Organ. 2000;78(8):956-963.
Mitruka K, Tsertsvadze T, Butsashvili M, et al. Launch of a Nationwide Hepatitis C Elimination Program-Georgia, April 2015. MMWR Morb Mortal Wkly Rep. 2015;64(28):753-757.
World Health Organization. Progress report on HIV, viral hepatitis and sexually transmitted infections, 2019 [Internet] [cited 2020 Apr 25]. https://www.google.com/search?q=Progress+report+on+HIV%2C+viral+hepatitis+and+sexually+transmitted+infections%2C+2019&oq=Progress+report+on+HIV%2C+viral+hepatitis+and+sexually+transmitted+infections%2C+2019&aqs=chrome..69i57j0.370j0j4&sourceid=chrome&ie=UTF-8
Leykum LK, El-Serag HB, Cornell J, Papadopoulos KP. Screening for hepatocellular carcinoma among veterans with hepatitis C on disease stage, treatment received, and survival. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2007;5(4):508-512.
Davila JA, Morgan RO, Richardson PA, Du XL, McGlynn KA, El-Serag HB. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatol Baltim Md. 2010;52(1):132-141.
Davila JA, Henderson L, Kramer JR, et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med. 2011;154(2):85-93.
Singal AG, Li X, Tiro J, et al. Racial, social, and clinical determinants of hepatocellular carcinoma surveillance. Am J Med. 2015;128(1):90.e1-7.
Forde KA. Ethnic disparities in chronic hepatitis B infection: African Americans and Hispanic Americans. Curr Hepatol Rep. 2017;16(2):105-112.
Simmons OL, Feng Y, Parikh ND, Singal AG. Primary care provider practice patterns and barriers to hepatocellular carcinoma surveillance. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2019;17(4):766-773.
Dalton-Fitzgerald E, Tiro J, Kandunoori P, Halm EA, Yopp A, Singal AG. Practice patterns and attitudes of primary care providers and barriers to surveillance of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2015;13(4):791-798.
Palmer LB, Kappelman MD, Sandler RS, Hayashi PH. Surveillance for hepatocellular carcinoma in a medicaid cirrhotic population. J Clin Gastroenterol. 2013;47(8):713-718.
Farvardin S, Patel J, Khambaty M, et al. Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis. Hepatology. 2017;65(3):875-884.
Papatheodoridis G, Dalekos G, Sypsa V, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol. 2016;64(4):800-806.
JFHOD/SNFGE.org. Société savante médicale française d’hépato-gastroentérologie et d'oncologie digestive [Internet] [cited 2020 Jul 10]. https://www.snfge.org/content/modeles-predictifs-de-carcinome
Audureau E, Carrat F, Layese R, et al. Personalized surveillance for hepatocellular carcinoma in cirrhosis-using machine learning adapted to HCV status. J Hepatol. 2020;73(6):1434-1445.
Pons M, Rodríguez-Tajes S, Esteban JI, et al. Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals. J Hepatol. 2020;72(3):472-480.
Nahon P, Cobat A. Human genetics of HCV infection phenotypes in the era of direct-acting antivirals. Hum Genet. 2020;139(6-7):855-863.
Tzartzeva K, Obi J, Rich NE, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology. 2018;154(6):1706-1718.e1.
Kim SY, An J, Lim Y-S, et al. MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma. JAMA Oncol. 2017;3(4):456-463.
Pocha C, Dieperink E, McMaken KA, Knott A, Thuras P, Ho SB. Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography-a randomised study. Aliment Pharmacol Ther. 2013;38(3):303-312.
Berhane S, Toyoda H, Tada T, et al. Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients. Clin Gastroenterol Hepatol. 2016;14(6):875-886.e6.
Lemoine M, Eholié S, Lacombe K. Reducing the neglected burden of viral hepatitis in Africa: strategies for a global approach. J Hepatol. 2015;62(2):469-476.
Shimakawa Y, Takao Y, Anderson ST, et al. The prevalence and burden of symptoms in patients with chronic liver diseases in The Gambia, West Africa. Palliat Med. 2015;29(2):184-185.
Stefan DC, Elzawawy AM, Khaled HM, et al. Developing cancer control plans in Africa: examples from five countries. Lancet Oncol. 2013;14(4):e189-e195.
Van Hees S, Muyindike W, Erem G, et al. Challenges associated with the roll-out of HCC surveillance in sub-Saharan Africa-the case of Uganda. J Hepatol. 2020;73(5):1271-1273.
Shimakawa Y, Bah E, Wild CP, Hall AJ. Evaluation of data quality at the Gambia national cancer registry. Int J Cancer. 2013;132(3):658-665.
Hong TP, Gow P, Fink M, et al. Novel population-based study finding higher than reported hepatocellular carcinoma incidence suggests an updated approach is needed. Hepatol Baltim Md. 2016;63(4):1205-1212.
Törner A, Stokkeland K, Svensson Å, et al. The underreporting of hepatocellular carcinoma to the cancer register and a log-linear model to estimate a more correct incidence. Hepatol Baltim Md. 2017;65(3):885-892.
Bray F, Ferlay J, Laversanne M, et al. Cancer incidence in five continents: inclusion criteria, highlights from volume X and the global status of cancer registration. Int J Cancer. 2015;137(9):2060-2071.
African Cancer Registry Programme. Welcome to African Cancer Registry [Internet] [cited 2020 Dec 27]. https://afcrn.org/
World Health Organization. WHO Mortality Database-WHO [Internet] [cited 2020 Dec 27]. https://www.who.int/data/data-collection-tools/who-mortality-database
Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941-1953.